2-Oxopyrrolidines and 6-oxoperhydropyrrolo[1,2-a]pyrazines as templates in the search for nonpeptide cholecystokinin ligands

Chemical and Pharmaceutical Bulletin

Volumn 46, Issue 5, 1998, Pages 782-786

  Martín Martínez, Mercedes ^a   Ballaz, Santiago ^b   Latorre, Miriam ^b   Herranz, Rosario ^a   García López, M Teresa ^a   Cenarruzabeitia, Edurne ^b   Del Río, Joaquín ^b   González Muñiz, Rosario ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

2 Oxopyrrolidine; Cholecystokinin mimetic; Perhydropyrrolo 1,2 a pyrazine

Indexed keywords

2 OXOPYRROLIDINE DERIVATIVE; 6 OXOPERHYDROPYRROLO[1,2 A]PYRAZINE DERIVATIVE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; LIGAND; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; NONHUMAN; PROTEIN CONFORMATION; STRUCTURE ANALYSIS;

EID: 2642710900     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.46.782     Document Type: Article

References (15)

1. González-Muñiz R., Domínguez M.J., Martín-Martínez M., Herranz R., García-López M. T., Barber A., Ballaz S., Del Rio J., Bioorg. Med. Chem. Lett., 6, 967-972 (1996).
2. a) Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R.D., Woodruff G. N., Proc. Natl Acad. Sci. U.S.A., 87, 6728-6732 (1990);
3. b) Blommaert A. G. S., Weng J.-H., Dorville A., McCort I., Ducos B., Durieux C., Roques B. P., J. Med. Chem., 36, 2868-2877 (1993);
4. Waldford S. P., Campbell M. M., Horwell D. C., J. Pharm. Pharmacol., 48, 188-191 (1996).
5. Flynn D. L., Villamil C. I., Becker D. P., Gullikson G. W., Moummi C., Yang D. C., Bioorg. Med. Chem. Left., 2, 1251-1256 (1992).
6. a) Ballaz S., Barber A., Fortuño A., Del Río J., Martín-Martínez M., Gómez-Monterrey I., Herranz R., González-Muñiz R., García-López M. T., Br. J. Pharmacol. 121, 759-767 (1997);
7. b) Martín-Martínez M., Bartolomé-Nebreda J. M.,Gómez-Monterrey I., González-Muñiz R., García-López M. T., Ballaz S., Barber A., Fortuño A., Del Río J., Herranz R., J. Med. Chem., 40, 3402-3407 (1997).
8. a) Farmer P. S., "Drug Design", Vol. X, ed. by Ariens E. J., Academic Press, New York, 1980, pp. 119-143;
9. b) Farmer P. S., Ariens E. J., Trends Pharmacol. Sci., 3, 362 (1982).
10. Martín-Martínez M., García-López M. T., Herranz R., González- Muñiz R., Tetrahedron Lett., 37, 2471-2474 (1996).
11. Martín-Martínez M., Herranz R., García-López M.T., González- Muñiz R., Tetrahedron, 52, 13991-14004 (1996).
12. Goudreau N., Weng J. H., Roques B. P., Biopolymers, 34, 155-169 (1994).
13. Daugé V., Bohme G. A., Crawley J. N., Durieux C., Stutzmann J. M., Feger J., Blanchard J. C., Roques B. P., Synapse, 6, 73-80 (1990).
14. Shiosaki K., Lin C. W., Kopka H., Tufano M. D., Bianchi B. R., Miller T. R., Witte D. G., Nadzan A. M., J. Med. Chem., 34, 2837-2842 (1991).
15. Lucaites V. L., Mendelsohn L. G., Mason N. R., Cohen M. L., J. Pharmacol. Exp. Ther., 256, 695-703 (1991).